Pradeep Natarajan (@pnatarajanmd) 's Twitter Profile
Pradeep Natarajan

@pnatarajanmd

Dir of Prev Cardiology @MassGeneralNews | Assoc Dir of Personalized Med @MassGenBrigham | Assoc Prof @harvardmed @HarvardChanSPH | Assoc Mem @broadinstitute

ID: 414751406

linkhttp://natarajanlab.mgh.harvard.edu calendar_today17-11-2011 12:54:42

16,16K Tweet

24,24K Takipçi

809 Takip Edilen

Deirdre Tobias, ScD (@deirdre_tobias) 's Twitter Profile Photo

🥩There have been **36 RCTs** testing effects of unprocessed red meat on cardiometabolic health vs. a range of control foods: 🍗🐟other meats, 🍞carb-rich foods, 🫘🫛🥦or veg/plant proteins. 23 of these comparisons were funded by meat industry...so what? nytimes.com/2025/05/20/wel…

Jaideep (@jaideeppatelmd) 's Twitter Profile Photo

Congrats Pradeep Natarajan on organizing - nice to see some familiar faces discussing the importance of #SouthAsianCVD. 🙏🏼 for mentioning our Practice Statement in AJPC (🔗sciencedirect.com/science/articl…) & Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 on discussing the role of #CAC testing. Johns Hopkins Ciccarone Center

OurHealth (@ourhealthstudy) 's Twitter Profile Photo

Wonderful forum hosted by Indiaspora MR Rangaswami ft Vivek Murthy w panelists Pradeep Natarajan Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 A. Mathur, R. Dash, & L. Palaniappan on cardiovascular health- what we know & what we don't know! Full broadcast youtube.com/watch?v=zi5NDt… 💜ourhealthstudy.org

nature (@nature) 's Twitter Profile Photo

Nature research paper: PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer go.nature.com/3SdcIft

Nick Leeper (@nickleeper78) 's Twitter Profile Photo

Very cool to see this important study from superstar vascular surgery resident, Alyssa Flores. Way to go Alyssa continuing to round out your training and make the most of the incredible environment provided by Pradeep. We are excited watching your continued scientific growth!

gVasc Study (@gvascstudy) 's Twitter Profile Photo

#WomensHealthMonth 💟➡️ Visit gvascstudy.org to learn more about the study investigating the genetic factors behind why SCAD happens and why it mostly occurs in women. #SCAD #SCADawareness #hearthealth #pregnancyhealth #Cardiology #MGH

#WomensHealthMonth 💟➡️ Visit gvascstudy.org to learn more about the study investigating the genetic factors behind why SCAD happens and why it mostly occurs in women. #SCAD #SCADawareness #hearthealth #pregnancyhealth #Cardiology #MGH
Veera Rajagopal  (@doctorveera) 's Twitter Profile Photo

A great paper in Nature Genetics from the David R. Liu and Ricardo Mouro Pinto labs shows a promising therapeutic strategy using gene editing to prevent repeat expansions in trinucleotide repeat disorders. Some of the most elegant therapeutic designs come from Nature. Human genetics

A great paper in <a href="/NatureGenet/">Nature Genetics</a> from the <a href="/davidrliu/">David R. Liu</a> and Ricardo Mouro Pinto labs shows a promising therapeutic strategy using gene editing to prevent repeat expansions in trinucleotide repeat disorders.

Some of the most elegant therapeutic designs come from Nature. Human genetics
Mass General Vascular (@mghvascular) 's Twitter Profile Photo

The gVasc Study is live—thanks in part to the efforts of resident Tiffany Bellomo! This important initiative aims to uncover the genetic foundations of SCAD by sequencing as many patients as possible. SCAD survivors can self-enroll today at gvascstudy.org.

The <a href="/gvascstudy/">gVasc Study</a> is live—thanks in part to the efforts of resident <a href="/BellomoTiffany/">Tiffany Bellomo</a>! This important initiative aims to uncover the genetic foundations of SCAD by sequencing as many patients as possible. SCAD survivors can self-enroll today at gvascstudy.org.
Pradeep Natarajan (@pnatarajanmd) 's Twitter Profile Photo

Among those with SBP >150 mmHg on indapamide, amlodipine, or olmesartan, the addition of zilbesiran (angiotensinogen siRNA) v placebo led to -12.1, -9.7, and -4.5 mmHg 24h mean ambulatory SBP change at 3mo. Increased rates of hyperkalemia, hypotension, and AKI.

Among those with SBP &gt;150 mmHg on indapamide, amlodipine, or olmesartan, the addition of zilbesiran (angiotensinogen siRNA) v placebo led to -12.1, -9.7, and -4.5 mmHg 24h mean ambulatory SBP change at 3mo. Increased rates of hyperkalemia, hypotension, and AKI.